GQ1001 is an innovative HER2-targeting ADC developed using Genequantum's cutting-edge continuous flow intelligent Ligase Dependent Conjugation (iLDC) technology and a unique "ring-opening" linker. It exhibits remarkable homogeneity, druggability, and exceptional stability in both in vivo and in vitro settings. Currently undergoing evaluation in global multi-center clinical trials for the treatment of HER2-positive advanced solid tumors (Clinical Trial ID: CXSL2000385), GQ1001 has demonstrated a superior safety profile and broader therapeutic window when compared to Kadcyla®. These features position it with significant developmental value and market potential.
GQ1005 is the next-generation HER2-targeting ADC developed by Genequantum, utilizing its proprietary iLDC technology, a cleavable "open-ring" linker, and a potent Topoisomerase I inhibitor. This innovative drug offers an exceptional bystander effect, making it well-suited for treating HER2 low/medium expressing breast cancer, gastric cancer, NSCLC and other advanced solid tumors (Clinical Trial ID: CXSL2200350). Preclinical data demonstrate GQ1005's superior stability, safety, and equivalent or superior anti-tumor activity compared to competing products. The drug is currently under evaluation in multi-center clinical trials.
GQ1010 is the next-generation Trop2-targeting ADC, developed using Genequantum's iLDC technology, a cleavable "open-ring" linker, and a novel Topoisomerase I inhibitor. In direct comparison with competing products, GQ1010 displays distinct preclinical advantages, including superior stability, safety, and efficacy. In April 2023, Genequantum exclusively licensed the global development and commercialization rights of GQ1010 (excluding Greater China, comprising Mainland China, Hong Kong, Macau, and Taiwan) to Pyramid Biosciences. This strategic collaboration brought Genequantum a substantial upfront payment of $20 million, with the potential for up to $1 billion in milestone payments and tiered royalties based on net sales.
GQ1011 is a first-in-class ADC targeting FGFR3, developed through a collaboration between Genequantum and Aimed Bio, a biotech company based in Korea. GQ1011 leverages Genequantum's iLDC technology, features a cleavable "open-ring" linker, and incorporates a novel Topoisomerase I inhibitor. GQ1011 has demonstrated potent anti-tumor efficacy against a range of FGFR3 alterations and overexpression in preclinical models. Furthermore, it exhibits a high level of tolerance in non-human primates (NHP), indicating a promising safety profile for further development. Currently, GQ1011 is progressing through IND enabling studies.